Dupilumab Demonstrates Significant Clinical Improvements in Patients with Eosinophilic Esophagitis
Dupilumab demonstrated positive and clinically-meaningful improvements in patients ≥12 years of age with eosinophilic esophagitis (EoE) in Part A of pivotal Phase 3 trial, according to a press release.
In the trial, 81 patients ≥12 years of age with EoE were treated with dupilumab 300 mg weekly (n = 42) or placebo (n = 39). At week 24, patients in the treatment group had a 69% reduction in symptoms from baseline compared to 32% for those in the placebo group. Patients treated with dupilumab experienced a 21.92 point improvement in disease symptoms, measured by the Dysphagia Symptom Questionnaire, compared to a 9.60 point improvement for the placebo group.
“Eosinophilic esophagitis can be debilitating, and there are no approved treatment options. It impacts patients’ ability to eat, causes severe pain and often results in repeated emergency room visits and medical procedures,” said George D. Yancopoulos, MD, PhD, Co-Founder, President and Chief Scientific Officer of Regeneron in a press release. “These data are particularly impressive, as Dupixent not only dramatically reduced eosinophils in the esophagus, but also improved all clinical, anatomic and histologic measures of the disease. In the past, EoE was thought to be a disease caused by eosinophils, but other biologics that decrease eosinophils in the esophagus did not demonstrate consistent clinical or anatomical improvements. These Dupixent results demonstrate EoE is caused by multiple aspects of type 2 inflammation, driven by interleukin-4 and interleukin-13. EoE is the fourth atopic or type 2 inflammatory disease in which Dupixent has pivotal data demonstrating significant efficacy.”
Read the full press release here.
Source: Regeneron Pharmaceuticals
